Cardioprotection in Drug-Induced Cardiotoxicity

Dear Colleagues,

More people are surviving cancer due to improved screening programmes and treatment options; however, many of these survivors go on to develop cardiac problems because of the drugs used to treat their cancer. This increased survival has highlighted the negative impact of some anticancer drugs on the heart. For example, Doxorubicin (Adriamycin), Fluoropyrimidines, and immune checkpoint inhibitors are effective drugs in the treatment of cancer, but they have been linked to significant cardiotoxic effects which affect morbidity and mortality. For many of these cancers, there is no equally effective alternative drug. Thus, an option is to cotreat these patients with an agent that minimises cardiotoxicity. However, very few such agents exist.

This Special Issue seeks to explore novel cardioprotective targets for drug-induced cardiotoxicity as well as innovative strategies for identifying and investigating cardioprotective agents in drug-induced cardiotoxicity. A better understanding of molecular mechanisms together with innovative solutions will help to shape the future of pharmacotherapy. This Special Issue welcomes review articles and primary research on the following (or related) topics:

1. Novel molecular drug targets for protecting the heart in drug-induced cardiotoxicity (including, but not limited to, RNA therapeutics, epigenetic targets, gut–microbiome interactions, etc.);
2. New approaches to existing molecular targets used to protect the heart in drug-induced cardiotoxicity;
3. Novel methods and models for the identification of molecules and pathways that can protect the heart in drug-induced cardiotoxicity (including, but not limited to, computational methods, cell models, novel molecular methods, pharmacogenomics, etc.).

Dr. Roisin Kelly-Laubscher
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cardioprotection
• cardiotoxicity
• anthracycline
• cardiac dysfunction
• heart failure